The precise quantitative similarity of the tumor suppressive effects across KRAS variants is particularly striking because it implies that such effects can be robust to extreme (>tenfold) differences in oncogenic potential, differences in biochemical properties and enzymatic activities31, 34, and diminishing-returns epistasis7–9. The gene discussed is KRAS; the disease is neoplasm.